Lam-ubol A,
Rungsiyanont S, Vacharotayangul P, Sappayatosok K, Chankanka O. Oral
manifestations, salivary flow rates and Candida species in Thai
HIV-infected patients. J Clin Exp Dent. 2019;11(2):e138-45.
doi:10.4317/jced.55384
http://dx.doi.org/10.4317/jced.55384
_____________________________________________________________________________________________________________________________
References
|
1. Nittayananta W,
Talungchit S, Jaruratanasirikul S, Silpapojakul K, Chayakul P, Nilmanat A, et
al. Effects of long-term use of HAART on oral health status of HIV-infected
subjects. J
Oral Pathol Med. 2010;39:397-406. |
|
|
|
|
|
2.
Ortega KL, Vale DA, Magalhaes MH. Impact of
PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected
patients. J Oral Pathol Med. 2009;38:489-94. |
|
|
|
|
|
3. Low A, Gavriilidis G,
Larke N, MR BL, Drouin O, Stover J, et al. Incidence of Opportunistic
Infections and the Impact of Antiretroviral Therapy Among HIV-Infected Adults
in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
Clin Infect Dis. 2016;62:1595-603. |
|
|
|
|
|
4. Diz Dios P, Scully C.
Antiretroviral therapy: effects on orofacial health and health care. Oral Dis. 2014;20:136-45. |
|
|
|
|
|
5. Navazesh M, Mulligan R,
Karim R, Mack WJ, Ram S, Seirawan H, et al. Effect of HAART on salivary gland
function in the Women's Interagency HIV Study (WIHS). Oral Dis. 2009;15:52-60. |
|
|
|
|
|
6. Fethi T, Asma J, Amine
SM, Amel EB, Taoufik BC, Mohamed C, et al. Effects on immunological and
virological outcome of patients using one protease inhibitor or one
non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral
therapy: normal clinical practice versus clinical trial findings. Curr HIV Res.
2005;3:271-6. |
|
|
|
|
|
7. Bartlett JA, Fath MJ,
Demasi R, Hermes A, Quinn J, Mondou E, et al. An updated systematic overview
of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20:2051-64. |
|
|
|
|
|
8. Li YY, Chen WY, Li X, Li
HB, Li HQ, Wang L, et al. Asymptomatic oral yeast carriage and antifungal
susceptibility profile of HIV-infected patients in Kunming, Yunnan Province
of China. BMC
Infect Dis. 2013;13:46. |
|
|
|
|
|
9. Thanyasrisung P,
Kesakomol P, Pipattanagovit P, Youngnak-Piboonratanakit P, Pitiphat W,
Matangkasombut O. Oral Candida carriage and immune status in Thai human
immunodeficiency virus-infected individuals. J Med Microbiol. 2014;63:753-9. |
|
|
|
|
|
10.
Delgado AC, de Jesus Pedro R, Aoki FH, Resende MR, Trabasso P, Colombo AL, et
al. Clinical and microbiological assessment of patients
with a long-term diagnosis of human immunodeficiency virus infection and
Candida oral colonization. Clin Microbiol Infect. 2009;15:364-71. |
|
|
|
|
|
11. Hung CC, Yang YL,
Lauderdale TL, McDonald LC, Hsiao CF, Cheng HH, et al. Colonization of human
immunodeficiency virus-infected outpatients in Taiwan with Candida species. J
Clin Microbiol. 2005;43:1600-3. |
|
|
|
|
|
12. Wu CJ, Lee HC, Yang YL,
Chang CM, Chen HT, Lin CC, et al. Oropharyngeal yeast colonization in
HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and
intravenous drug use matter. Clin Microbiol Infect. 2012;18:485-90. |
|
|
|
|
|
13. Owotade FJ, Patel M,
Ralephenya TR, Vergotine G. Oral Candida colonization in HIV-positive women:
associated factors and changes following antiretroviral therapy. J Med Microbiol.
2013;62:126-32. |
|
|
|
|
|
14. Paula SB, Morey AT,
Santos JP, Santos PM, Gameiro DG, Kerbauy G, et al. Oral Candida colonization
in HIV-infected patients in Londrina-PR, Brazil: antifungal susceptibility
and virulence factors. J
Infect Dev Ctries. 2015;9:1350-9. |
|
|
|
|
|
15.
Ribeiro Ribeiro AL, de Alencar Menezes TO, de Melo Alves-Junior S, de Menezes
SA, Marques-da-Silva SH, Rosario Vallinoto AC. Oral carriage of Candida species in HIV-infected patients during
highly active antiretroviral therapy (HAART) in Belem, Brazil. Oral Surg Oral
Med Oral Pathol Oral Radiol. 2015;120:29-33. |
|
|
|
|
|
16. Borg-von Zepelin M,
Meyer I, Thomssen R, Wurzner R, Sanglard D, Telenti A, et al. HIV-Protease
inhibitors reduce cell adherence of Candida albicans strains by inhibition of
yeast secreted aspartic proteases. J Invest Dermatol. 1999;113:747-51. |
|
|
|
|
|
17.
Cassone A, Tacconelli E, De Bernardis F, Tumbarello M, Torosantucci A, Chiani
P, et al. Antiretroviral therapy with protease inhibitors has
an early, immune reconstitution-independent beneficial effect on Candida
virulence and oral candidiasis in human immunodeficiency virus-infected
subjects. J
Infect Dis. 2002;185:188-95. |
|
|
|
|
|
18.
Rao KV, Chitturi RT, Kattappagari KK, Kantheti LP, Poosarla C, Baddam VR. Impact of highly active antiretroviral therapy on
oral manifestations of patients with human immunodeficiency virus/acquired
immuno deficiency syndrome in South India. Indian J Sex Transm Dis. 2015;36:35-9. |
|
|
|
|
|
19. Satyakiran GV, Bavle RM,
Alexander G, Rao S, Venugopal R, Hosthor SS. A relationship between CD4 count
and oral manifestations of human immunodeficiency virus-infected patients on
highly active antiretroviral therapy in urban population. J Oral Maxillofac
Pathol. 2016;20:419-26. |
|
|
|
|
|
20. Batavia AS, Secours R,
Espinosa P, Jean Juste MA, Severe P, Pape JW, et al. Diagnosis of
HIV-Associated Oral Lesions in Relation to Early versus Delayed
Antiretroviral Therapy: Results from the CIPRA HT001 Trial. PLoS One. 2016;11:e0150656. |
|
|
|
|
|
21. Vacharotayangul P,
Rungsiyanont S, Lam-Ubol A, Pankam T, Rodbamrung P, Naorungroj S, et al.
Higher prevalence of oral human papillomavirus infection in HIV-positive than
HIV-negative Thai men and women. Cancer Epidemiol. 2015;39:917-22. |
|
|
|
|
|
22. Navazesh M, Mulligan R,
Barron Y, Redford M, Greenspan D, Alves M, et al. A 4-year longitudinal
evaluation of xerostomia and salivary gland hypofunction in the Women's
Interagency HIV Study participants. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 2003;95:693-8. |
|
|
|
|
|
23. Silverberg MJ, Gore ME,
French AL, Gandhi M, Glesby MJ, Kovacs A, et al. Prevalence of clinical
symptoms associated with highly active antiretroviral therapy in the Women's
Interagency HIV Study. Clin
Infect Dis. 2004;39:717-24. |
|
|
|
|
|
24. Kumar JV, Baghirath PV,
Naishadham PP, Suneetha S, Suneetha L, Sreedevi P. Relationship of long-term
highly active antiretroviral therapy on salivary flow rate and CD4 Count
among HIV-infected patients. J Oral Maxillofac Pathol. 2015;19:58-63. |
|
|
|
|
|
25. Owotade FJ, Patel M.
Virulence of oral Candida isolated from HIV-positive women with oral
candidiasis and asymptomatic carriers. Oral Surg Oral Med Oral Pathol Oral
Radiol. 2014;118:455-60. |
|
|
|
|
|
26.
Mushi MF, Mtemisika CI, Bader O, Bii C, Mirambo MM, Gross U, et al. High Oral Carriage of Non-albicans Candida spp.
among HIV-infected individuals. Int J Infect Dis. 2016;49:185-8. |
|
|
|
|
|
27.
Dos Santos Abrantes PM, McArthur CP, Africa CW. Multi-drug resistant oral Candida species isolated from HIV-positive
patients in South Africa and Cameroon. Diagn Microbiol Infect Dis. 2014;79:222-7. |
|
|
|
|
|
28. Pappas PG, Kauffman CA,
Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Executive Summary:
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by
the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:409-17. |
|
|
|
|
|
29.
Ferreira AV, Prado CG, Carvalho RR, Dias KS, Dias AL. Candida albicans and non-C. albicans Candida
species: comparison of biofilm production and metabolic activity in biofilms,
and putative virulence properties of isolates from hospital environments and
infections. Mycopathologia.
2013;175:265-72. |
|
|
|
|
|
30. Jiang L, Yong X, Li R,
Peng Y, Liu W, Qin Q, et al. Dynamic analysis of oral Candida carriage,
distribution, and antifungal susceptibility in HIV-infected patients during
the first year of highly active antiretroviral therapy in Guangxi, China. J Oral Pathol
Med. 2014;43:696-703. |
|